Product Description
11_-hydroxysteroid dehydrogenase type 1 inhibitor for type 2 diabetes mellitus and metabolic syndrome (Sourced from: https://pubmed.ncbi.nlm.nih.gov/21272190/)
Mechanisms of Action: 11beta-HSD1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hypertension|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00274716 |
NCT00274716 | P2 |
Completed |
Hypertension |
2007-01-01 |
2022-05-04 |
Primary Endpoints |
|
NCT00543595 |
NCT00543595 | P2 |
Completed |
Type 2 Diabetes |
2005-05-01 |
2022-05-04 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|